Comments
Healthcare player Zydus Cadila (Cadila Healthcare Ltd) on Wednesday informed that the company has received final approval from the US drug regulator to market its anti-diabetic drug.
The US Food and Drug Administration (USFDA) gave its final approval to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg in the US. Glyburide, which is an anti-diabetic drug, will be produced at the Zydus Group’s formulations manufacturing facility at Baddi in Himachal Pradesh.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.